Screener
ANI Pharmaceuticals ANIP Contingent consideration fair value adjustment
Contingent consideration fair value adjustment at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's contingent consideration fair value adjustment?
- ANI Pharmaceuticals (ANIP) reported contingent consideration fair value adjustment of -$622K in Q2 2026.
- What is the long-term trend for ANI Pharmaceuticals's contingent consideration fair value adjustment?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's contingent consideration fair value adjustment has grown at a 183.5% compound annual growth rate (CAGR), from $500K to -$32.29M.
- What does contingent consideration fair value adjustment mean?
- Represents non-cash adjustments to the fair value of earn-out provisions or contingent payments related to past business acquisitions. Fluctuations in this value reflect changes in the estimated probability or timing of achieving performance-based milestones. This metric is critical for assessing the impact of acquisition-related liabilities on reported net income.
Ask your AI about ANI Pharmaceuticals's contingent consideration fair value adjustment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude